Renal Cell Carcinoma Clinical Trial
Official title:
A Phase 1, Multiple-Dose, Dose-Escalation Trial of PT2385 Tablets, a HIF-2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
PART 1: The primary objective of this study is to identify the maximum tolerated dose (MTD) of MK-3795, formerly called PT2385 and/or the recommended Phase 2 dose (RP2D) of MK-3795 in patients with advanced clear cell renal cell carcinoma (ccRCC). PART 2: The primary objective of this study is to identify the MTD of MK-3795 up to the RP2D, in combination with nivolumab, in patients with advanced ccRCC.As of Amendment 09 (29 Mar 2024), participants with advanced ccRCC will transition from MK-3795 to belzutifan (MK-6482) in combination with nivolumab or belzutifan alone. PART 3: The primary objective of this study is to identify the MTD of MK-3795 up to the RP2D, in combination with cabozantinib tablets, in patients with advanced ccRCC.
Status | Active, not recruiting |
Enrollment | 110 |
Est. completion date | November 30, 2026 |
Est. primary completion date | January 31, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria PART 1 - Has locally advanced or metastatic clear cell renal cell carcinoma (ccRCC) and has progressed during treatment with at least one prior therapeutic regimen - Has a life expectancy of = 3 months - Has adequate organ function - Able to swallow oral medications PART 2 - In addition to PART 1 - Received no more than three prior systemic treatment regimens in the advanced or metastatic setting - Must have received at least one but not more than two prior anti-angiogenic therapy regimens PART 3 - In addition to PART 1 - Must have received at least one vascular endothelial growth factor receptor (VEGFR) targeting tyrosine kinase inhibitor Exclusion Criteria PART 1 - Has a history of untreated brain metastasis or history of leptomeningeal disease or spinal cord compression - Has failed to recover from the reversible effects of prior anticancer therapy - Has uncontrolled or poorly controlled hypertension - Is receiving warfarin anticoagulant therapy or expected to require warfarin - Has had any major cardiovascular event within 6 months prior to study drug administration - Has any other clinically significant cardiac, respiratory, or other medical or psychiatric condition that might interfere with participation in the trial or interfere with the interpretation of trial results - Has had major surgery within 4 weeks before first study drug administration - Has known human immunodeficiency virus (HIV) infection - Has an active infection requiring systemic treatment - Is participating in another therapeutic clinical trial PART 2 - In addition to PART 1 - Has received prior immunotherapy - Has any active or recent history of a known or suspected autoimmune disease PART 3 - In addition to PART 1 - Has gastrointestinal (GI) disorders - Has any history of congenital long QT syndrome |
Country | Name | City | State |
---|---|---|---|
United States | Emory University Winship Cancer Institue | Atlanta | Georgia |
United States | University of Colorado Cancer Center | Aurora | Colorado |
United States | University of Maryland - Greenebaum Cancer Center | Baltimore | Maryland |
United States | Beth Israel Deconess Medical Center | Boston | Massachusetts |
United States | Dana-Farber Cancer Institute | Boston | Massachusetts |
United States | Massachusetts General Hospital - Cancer Center | Boston | Massachusetts |
United States | Rush University Medical Center | Chicago | Illinois |
United States | Cleveland Clinic | Cleveland | Ohio |
United States | The Ohio State University | Columbus | Ohio |
United States | UT Southwestern Medical Center | Dallas | Texas |
United States | Barbara Ann Karmanos Cancer Institute | Detroit | Michigan |
United States | Virginia Cancer Specialists | Fairfax | Virginia |
United States | The West Clinic | Germantown | Tennessee |
United States | Indiana University Simon Cancer Center | Indianapolis | Indiana |
United States | Cedars-Sinai Medical Center | Los Angeles | California |
United States | University of Miami - Sylvester Comprehensive Cancer Center | Miami | Florida |
United States | Medical College of Wisconsin | Milwaukee | Wisconsin |
United States | Tennessee Oncology | Nashville | Tennessee |
United States | Vanderbilt Medical Center | Nashville | Tennessee |
United States | Yale School of Medicine | New Haven | Connecticut |
United States | Mount Sinai Heath System | New York | New York |
United States | Fox Chase Cancer Center | Philadelphia | Pennsylvania |
United States | University of Pittsburg Medical Center | Pittsburgh | Pennsylvania |
United States | Swedish Cancer Institute | Seattle | Washington |
United States | University of Washington | Seattle | Washington |
Lead Sponsor | Collaborator |
---|---|
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Maximum Tolerated Dose (MTD) | MTD of MK-3795 will be determined. MTD will be defined as the dose level at which 2 or more participants experience a dose limiting toxicity (DLT) which will be deemed intolerable and the dose level below will be declared the MTD. | Part 1: 3 Weeks, Part 2: 4 Weeks, Part 3: 4 Weeks | |
Primary | Recommended Phase 2 Dose (RP2D) | The RP2D of MK-3795 will be determined. The RP2D will be determined based on the MTD (or the optimal biological dose (OBD) if the MTD is not identified), the overall safety profile with continued treatment, and pharmacokinetic (PK) profile. | Part 1: 3 Weeks; Part 2: 4 Weeks, Part 3: 4 Weeks | |
Secondary | Number of Participants Who Experience an Adverse Event (AE) | An AE is defined as any untoward medical occurrence in a participant administered a study treatment which did not necessarily have to have a causal relationship with this treatment. An AE could be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that is temporally associated with the use of study treatment, is also an AE. The number of participants who experience an AE will be presented. | Up to approximately 9 years | |
Secondary | Best Response (BOR) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) | BOR is the best tumor response recorded up until documentation of progression of disease (PD) or death from any cause, or until the patient withdraws consent. Per RECIST 1.1, PD is defined as =20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of =5 mm. The appearance of one or more new lesions is also considered PD. | Up to approximately 1 year | |
Secondary | Objective Response Rate (ORR) per RECIST 1.1 | ORR is defined as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR based on RECIST 1.1 will be presented. | Up to approximately 1 year | |
Secondary | Progression-Free Survival (PFS) per RECIST 1.1 | PFS is defined as the time from the first dose of MK-3795 to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as =20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of =5 mm. The appearance of one or more new lesions is also considered PD. | Up to approximately 9 years | |
Secondary | Duration of Response (DOR) per RECIST 1.1 | For participants who demonstrate a confirmed Complete Response (CR: Disappearance of all target lesions) or confirmed Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered PD. The median DOR will be presented. | Up to approximately 1 year | |
Secondary | Clinical Benefit Rate (CBR) per RECIST 1.1 | CBR is defined as the percentage of participants who achieve clinical benefit. Clinical benefit is defined as a best response of CR (Disappearance of all target lesions), PR (At least a 30% decrease in the sum of diameters of target lesions) or stable disease (SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease [PD: At least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD.]). | Up to approximately 1 year | |
Secondary | Maximum concentration (Cmax) of Study Treatment | Blood samples will be collected at designated timepoints for the determination of Cmax. Cmax was defined as the maximum concentration of study treatment is reached. | At designated timepoints (up to 106 days) | |
Secondary | Time to Maximum Concentration (Tmax) of Study Treatment | Blood samples will be collected at designated timepoints the determination of Tmax. Tmax is defined as the time to the maximum concentration of study treatment reached. | At designated timepoints (up to 106 days) | |
Secondary | Terminal half-life (t½?z) of Study Treatment | Blood samples will be collected at designated timepoints for the determination of (t½?z). (t½?z) is defined as the time required for the plasma concentration of study drug to decrease 50% in the final stage of its elimination. | At designated timepoints (up to 106 days) | |
Secondary | Area Under the Concentration-Time Curve From 0 to Infinity (AUC0-inf) of Study Treatment | Blood samples will be collected at designated timepoints for the determination of AUC0-inf. AUC0-inf is the area under the serum concentration-time curve from time zero to infinity. | At designated timepoints (up to 106 days) | |
Secondary | Area Under the Concentration-Time Curve From 0 to Inf Extrapolated (AUC0-inf Extrap) of Study Treatment | Blood samples were collected at designated timepoints for the determination of AUC0-inf extrapolated. AUC0-inf extrapolated is a measure of mean concentration in serum from time zero to infinity. | At designated timepoints (up to 106 days) | |
Secondary | Area Under the Concentration-Time Curve From 0 to 12 Hours (AUC0-12) of Study Treatment | Blood samples were collected at designated timepoints for the determination of AUC0-12. AUC0-12 is a measure of mean concentration in serum from time zero to 12 hours. | At designated timepoints (up to 106 days) | |
Secondary | Area Under the Plasma Concentration-time Curve From Time 0 to Last (AUC0-last) of Study Treatment | Blood samples were collected at designated timepoints for the determination of AUC0-last. AUC0-last is a measure of mean concentration in serum from time zero to last measurable concentration. | At designated timepoints (up to 106 days) | |
Secondary | Apparent Volume of Distribution (Vz/F) of Study Treatment | Blood samples were collected at designated timepoints for the determination of Vz/F. Vz/F is a the volume of study drug that would need to be uniformly distributed to produce desired serum concentration. F is the fraction of the dose absorbed. | At designated timepoints (up to 106 days) | |
Secondary | Apparent Clearance (CL/F) of Study Treatment | Blood samples were collected at designated timepoints for the determination of CL/F. CL/F is a the volume of plasma from which study drug was eliminated per unit time. F is the fraction of the dose absorbed. | At designated timepoints (up to 106 days) | |
Secondary | Accumulation Ratio (RAC) | Blood samples were collected at designated timepoints for the determination of RAC. RAC is calculated as AUC0-12 at steady state divided by AUC0-12 after first dose. | At designated timepoints (up to 106 days) | |
Secondary | Mean Plasma Concentration of Erythropoietin (EPO) Level | Blood samples will be collected at designated timepoints to measure EPO level. The mean concentration of EPO level will be reported. | At designated timepoints (up to 106 days) | |
Secondary | Mean Plasma Concentration of Plasminogen Activator Inhibitor 1 (PAI-1) Level | Blood samples will be collected at designated timepoints to measure PAI-1 level. The mean concentration of PAI-1 level will be reported. | At designated timepoints (up to 106 days) | |
Secondary | Mean Plasma Concentration of Insulin Growth Factor Binding Protein 3 (IGFBP3) Level | Blood samples will be collected at designated timepoints to measure IGFBP3 level. The mean concentration of IGFBP3 level will be reported. | At designated timepoints (up to 106 days) | |
Secondary | Mean Plasma Concentration of Vascular Endothelial Growth Factor A (VEGFa) Level | Blood samples will be collected at designated timepoints to measure VEGFa level. The mean concentration of VEGFa level will be reported. | At designated timepoints (up to 106 days) | |
Secondary | Percent Change from Baseline in the EPO Level | Blood samples will be collected at designated timepoints to measure EPO level. The percent change from baseline in EPO level up to approximately Week 16 will be reported. | Baseline and up to approximately Week 16 | |
Secondary | Percent Change from Baseline in the PAI-1 Level | Blood samples will be collected at designated timepoints to measure PAI-1 level. The percent change from baseline in PAI-1 level up to approximately Week 16 will be reported. | Baseline and up to approximately Week 16 | |
Secondary | Percent Change from Baseline in the IGFBP3 Level | Blood samples will be collected at designated timepoints to measure IGFBP3 level. The percent change from baseline in IGFBP3 level up to approximately Week 16 will be reported. | Baseline and up to approximately Week 16 | |
Secondary | Percent Change from Baseline in the VEGFa | Blood samples will be collected at designated timepoints to measure VEGFa level. The percent change from baseline in VEGFa level up to approximately Week 16 will be reported. | Baseline and up to approximately Week 16 | |
Secondary | Antitumor Activity | Antitumor activity will be assessed by non-contrast or contrast computerized tomography (CT) or magnetic resonance imaging (MRI) at baseline, during Week 6, and every 9 weeks thereafter up to approximately 1 year. | Baseline, at Week 6 and every 9 Weeks thereafter up to approximately 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04987203 -
Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
|
Phase 3 | |
Recruiting |
NCT06391879 -
Establishment of a Multidimensional Prediction Model for the Natural Course of VHL Disease-related Renal Cell Carcinoma
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
Terminated |
NCT03655613 -
APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Withdrawn |
NCT05418387 -
A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona
|
N/A | |
Recruiting |
NCT04623502 -
An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy
|
N/A | |
Completed |
NCT02853344 -
Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427)
|
Phase 2 | |
Terminated |
NCT04088500 -
A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma
|
Phase 2 | |
Completed |
NCT05070637 -
Circulating Tumor Cell Reducing No-touch Nephrectomy
|
N/A | |
Active, not recruiting |
NCT03634540 -
A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
|
Phase 2 | |
Not yet recruiting |
NCT06049030 -
A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma
|
Phase 1 | |
Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
Completed |
NCT01358721 -
Phase I Biomarker Study (BMS-936558)
|
Phase 1 | |
Active, not recruiting |
NCT04503148 -
Anesthesia and Cancer Study: Renal Cell Carcinoma
|
N/A | |
Completed |
NCT02386826 -
INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme
|
Phase 1 | |
Not yet recruiting |
NCT05808608 -
A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03323710 -
Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma
|
Phase 2 | |
Completed |
NCT03052504 -
Prospective Versus Retrospective Complications in Radical Cystectomy and Nephrectomy
|